Glenn Dubin, Principal

Glenn Dubin

Glenn Dubin is an American businessman, philanthropist and investor. He is the principal of Dubin & Co., a private investment company based in New York. Mr. Dubin co-founded Highbridge Capital Management LLC, an alternative asset management company in 1992. In 2009, Highbridge was acquired by JP Morgan Asset Management, and Mr. Dubin remained at the helm to oversee the transition.

Dubin is widely recognized as one of the pioneers of the hedge fund industry, having founded and led a number of highly successful fund management businesses. In 2013, Mary Callahan Erdoes, CEO of JP Morgan Asset Management, stated that “Few people have changed an industry and created as unique a culture and firm as Glenn has. He has made extraordinary contributions to the alternative asset management industry and many philanthropic causes. We are grateful for all he has done for the firm, our employees, and the industry.”

In 2012, Mr. Dubin, along with a prominent group of investors, acquired Castleton Commodities International LLC (“CCI”) a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. The company ranks as one of the world’s leading independent energy merchants. Mr. Dubin is a member of the Board of Directors and the lead shareholder of the company.

In 2013, Mr. Dubin stepped down as Chairman and CEO of Highbridge to focus on Dubin & Co., a private investment company based in New York with investments in both private and publicly traded companies. He is active in investing in early-stage biotech companies that address unmet medical needs, as well as investing in early and late stage growth companies.

Mr. Dubin is a founder and former Board chair of the Robin Hood Foundation, a philanthropic organization in New York that applies investment principles to charitable giving. He is a Board member of Mount Sinai Medical Center where he and his wife, Eva Andersson-Dubin, MD, established the Dubin Breast Center, a leading institution for breast cancer research and clinical care. He is also a Board member and Executive Committee member of the Museum of Modern Art.

Career

Dubin began his career in finance in 1978 as an entry-level hire at E. F. Hutton & Co., a stock brokerage firm based in New York.

In 1984, Dubin and his childhood friend, Henry Swieca, took a leap of faith and set off to create their own investment firm, Dubin & Swieca Capital Management, an early fund-of-funds business, guided by the principles of modern portfolio theory. (In 2005, following years of successful growth, the firm was renamed Corbin Capital Partners as an ode to the intersection in Washington Heights where the founders first met when they were 5 years old.)

In 1992, Dubin and Swieca went on to create Highbridge Capital Management, a multi-strategy hedge fund firm named after the 19th Century aqueduct that connects Washington Heights to the Bronx. In 2004, J.P. Morgan Asset Management—a division of JPMorgan Chase—purchased a majority interest in Highbridge for a reported $1.3 billion dollars , and subsequently completed its purchase of the firm in 2009. After the purchase, Dubin remained Highbridge’s chief executive until July 2013.

In 2012, Dubin along with a prominent group of global investors acquired Castleton Commodities International LLC (“CCI”), (formerly Louis Dreyfus Highbridge Energy), a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. In 2015, CCI acquired Morgan Stanley’s Global Oil Merchanting business, and the combined company now ranks as one of the world’s leading independent energy merchants. Dubin held the position of non-executive chairman and continues to serve as a member of the Board of Directors and the firm’s lead shareholder.

In 2013, Dubin founded Engineers Gate LP, a proprietary quantitative trading company committed to building a next generation operating and technology platform for systematic trading strategies. Under Dubin’s leadership Engineers Gate grew to over 80 employees, including 26 PhDs. He served as the company’s Chairman until January 2020, before handing over the reins to Greg Eisner, his longtime business partner and protégé.

Since 2020, Dubin has focused more of his time and attention on philanthropy as well as direct investments in early-stage biotechnology companies that address unmet medical needs. He is also active in venture and growth equity investments often providing advice and mentorship to company founders.

 

Glenn Dubin is on LinkedIn